Big Pharma still heavily relies on sales from an ageing portfolio of products and the proportion of sales from newer medicines actually fell last year, after a decade of record research spending yielded few new winners.
The 2010 Pharmaceutical R&D Factbook, compiled by CMR International and released on Monday, painted a gloomy picture of the global pharmaceuticals sector.
New drugs launched within the last five years accounted for less than 7 percent of industry sales in 2009, down from 8 percent in 2008, the Factbook showed, highlighting the big problems that companies are having in trying to reinvigorate their portfolios. Continue reading →
Inovio Pharmaceuticals is a company that focuses on developing a new generation of vaccines called DNA vaccines. These are to prevent and treat cancers, influenza and other challenging diseases caused by, for example, HIV and HPV.
Inovio, announced today that the peer-reviewed journal Molecular Therapy has published a paper entitled “IL-28B/IFN-lambda3 Drives Granzyme B Loading and Significantly Increases CTL Killing Activity in Macaques.”
With this study, they have shown that they are able, with their innovative DNA vaccine technology-platform, to increase immune responses to diseases in non-human primates. Continue reading →
A young clinical-stage molecular imaging company called Avid Radiopharmaceuticals has developed compounds that tightly bind to amyloid plaques. Then by using PET scans, in vivo detection of amyloid plaques can be made possible (see figure). Alzheimer’s Disease is defined by the accumulation of brain amyloid and may be even caused by this brain amyloid. Continue reading →
Hi, my name is Kenneth. I am a young medical biologist specialized in business, management & entrepreneurship in Life Sciences.
With this blog I am establishing my first endeavors as an internet-entrepreneur. Here, I’d like to share with you interesting things about developments in the biotechnology and pharmaceutical industry. Continue reading →
